The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink

Cancer Causes and Control

Volumn 26, Issue 3, 2015, Pages 355-366

  O'Rorke M A ^a   Murray, L J ^a   Hughes, C M ^b   Cantwell, M M ^a   Cardwell, C R ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Anticoagulant; Cancer; Mortality; Survival; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CAUSE OF DEATH; COHORT ANALYSIS; COLORECTAL CANCER; DOSE RESPONSE; DRUG USE; FEMALE; HUMAN; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; VERY ELDERLY; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FACTUAL DATABASE; INCIDENCE; LUNG NEOPLASMS; MORTALITY; NEOPLASM METASTASIS; ORAL DRUG ADMINISTRATION; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BREAST NEOPLASMS; COHORT STUDIES; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; WARFARIN;

EID: 84925496886     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0511-2     Document Type: Article

References (42)

1. Gil-Bernabé AM, Lucotti S, Muschel RJ (2013) Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol 162:433–441. doi:10.1111/bjh.12381
2. Kakkar AK, Macbeth F (2010) Antithrombotic therapy and survival in patients with malignant disease. Br J Cancer 102(Suppl):S24–S29. doi:10.1038/sj.bjc.6605602
3. Kuderer NM, Ortel TL, Francis CW (2009) Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 27:4902–4911. doi:10.1200/JCO.2009.22.4584
4. Palumbo JS, Kombrinck KW, Drew AF et al (2000) Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96:3302–3309
5. Bobek V, Boubelik M, Fiserová A et al (2005) Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer 47:215–223. doi:10.1016/j.lungcan.2004.06.012
6. Im JH, Fu W, Wang H et al (2004) Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 64:8613–8619. doi:10.1158/0008-5472.CAN-04-2078
7. Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123–134. doi:10.1038/nrc3004
8. Bobek V, Kovarík J (2004) Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 58:213–219. doi:10.1016/j.biopha.2003.11.007
9. Hejna M, Raderer M, Zielinski CC (1999) Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91:22–36
10. Battinelli EM, Markens BA, Kulenthirarajan RA et al (2014) Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood 123:101–112. doi:10.1182/blood-2013-02-485011
11. Amirkhosravi A, Mousa SA, Amaya M et al (2010) Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis. Methods Mol Biol 663:241–259. doi:10.1007/978-1-60761-803-4_10
12. Maat B (1980) Selective macrophage inhibition abolishes warfarin-induced reduction of metastasis. Br J Cancer 41:313–316
13. Hilgard P, Schulte H, Wetzig G et al (1977) Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL). Br J Cancer 35:78–86
14. Brown JM (1973) A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases. Cancer Res 33:1217–1224
15. Bobek V, Boubelik M, Kovarík J, Taltynov O (2003) Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine. Neoplasma 50:148–151
16. McCulloch P, George WD (1989) Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth. Br J Cancer 59:179–183
17. Akl EA, Vasireddi SR, Gunukula S et al (2011) Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev. doi:10.1002/14651858.CD006466.pub3
18. Chahinian AP, Propert KJ, Ware JH et al (1989) A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7:993–1002
19. Maurer LH, Herndon JE, Hollis DR et al (1997) Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 15:3378–3387
20. Zacharski LR, Henderson WG, Rickles FR et al (1984) Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53:2046–2052
21. Daly L (1991) The first international urokinase/warfarin trial in colorectal cancer. Clin Exp Metastasis 9:3–11
22. Levine M, Hirsh J, Gent M et al (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886–889
23. Tagalakis V, Tamim H, Blostein M et al (2013) Risk of prostate cancer death in long-term users of warfarin: a population-based case–control study. Cancer Causes Control 24:1079–1085. doi:10.1007/s10552-013-0185-1
24. Tagalakis V, Tamim H (2010) The effect of warfarin use on clinical stage and histological grade of prostate cancer. Pharmacoepidemiol Drug Saf 19:436–439. doi:10.1002/pds.1943
25. García Rodríguez LA, Pérez Gutthann S (1998) Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 45:419–425
26. Dregan A, Moller H, Murray-Thomas T, Gulliford MC (2012) Validity of cancer diagnosis in a primary care database compared with linked cancer registrations in England. Population-based cohort study. Cancer Epidemiol 36:425–429. doi:10.1016/j.canep.2012.05.013
27. Khan NF, Harrison SE, Rose PW (2010) Validity of diagnostic coding within the general practice research database: a systematic review. Br J Gen Pract 60:e128–e136. doi:10.3399/bjgp10X483562
28. Khan NF, Perera R, Harper S, Rose PW (2010) Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 11:1. doi:10.1186/1471-2296-11-1
29. Hirsh J, Fuster V, Ansell J, Halperin JL (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107:1692–1711. doi:10.1161/01.CIR.0000063575.17904.4E
30. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367:1792–1802. doi:10.1056/NEJMoa1201735
31. Lévesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087. doi:10.1136/bmj.b5087
32. Chubak J, Boudreau DM, Wirtz HS et al (2013) Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst 105:1456–1462. doi:10.1093/jnci/djt211
33. Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR (2007) The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev 33:358–368. doi:10.1016/j.ctrv.2007.02.004
34. Smorenburg SM, Vink R, Otten HM et al (2001) The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 86:1586–1587
35. Stanford CF (1979) Anticoagulants in the treatment of small cell carcinoma of the bronchus. Thorax 34:113
36. Cunningham MS, Preston RJS, O’Donnell JS (2009) Does antithrombotic therapy improve survival in cancer patients? Blood Rev 23:129–135. doi:10.1016/j.blre.2008.10.002
37. Ryan JJ, Ketcham AS, Wexler H (1968) Warfarin treatment of mice bearing autochthonous tumors: effect on spontaneous metastases. Science 162:1493–1494
38. Agostino D, Cliffton EE, Girolami A (1966) Effect of prolonged coumadin treatment on the production of pulmonary metastases in the rat. Cancer 19:284–288
39. Walker JJ, Johnson JA, Wild SH (2013) Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. Lancet Diabetes Endocrinol 1:132–139. doi:10.1016/S2213-8587(13)70028-7
40. Sarfati D, Blakely T, Pearce N (2010) Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol 39:598–610. doi:10.1093/ije/dyp392
41. Lee AYY, Rickles FR, Julian JA et al (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23:2123–2129. doi:10.1200/JCO.2005.03.133
42. Gerotziafas GT, Papageorgiou C, Hatmi M et al (2008) Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb 36:204–211. doi:10.1159/000175158